Nadia Ekindi Ndongo

Metastatic Squamous Cell Carcinoma of Prostatic Origin: Identification Through Next Generation Sequencing and Treatment With Pembrolizumab: A Case Report

Arielle Jalbert, Sarah-Maria Sfairy, Nadia Ekindi Ndongo, Michel Pavic

Squamous cell carcinomas (SCCs) of prostatic origin are rare, representing 0.5% to 1% of all prostate carcinomas. They may be present at the diagnosis but are often discovered as a transformation of an adenocarcinoma previously treated with radiotherapy or androgen deprivation therapy. …

ca (code pays fourni par la source)

Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models

Lauren Daniel, Hugo Giguère, Léa J Custeau, Jacob L. Léger et autres

Non-muscle-invasive bladder cancer (NMIBC) can progress to muscle-invasive disease, with transurethral resection followed by Bacillus Calmette-Guérin (BCG) immunotherapy reducing this risk. Effective immunotherapies for BCG-resistant NMIBC are lacking. This study directly compares the efficacy of the oncolytic vesicular stomatitis virus (VSVd51) encoding …

ca (code pays fourni par la source)

The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Tess Aalto, Maria Abacan, Shirin Abadi, Farnoosh Abbas Aghababazadeh et autres

PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer

Frédéric Couture, Luojun Wang, Frédérik Dufour, Keena Chabot-Maheux et autres

The proprotein convertase PACE4 has demonstrated value as a viable therapeutic target in prostate cancer (PCa). A novel isoform named PACE4-altCT, which arises in neoplastic lesions, plays an important role in tumor progression and has been validated as a pharmacological target. With …

ca (code pays fourni par la source)